HIV-1 cell entry and advances in viral entry inhibitor therapy

Journal of Clinical Virology

Volumn 26, Issue 2, 2003, Pages 121-132

  Cooley, Louise A ^a   Lewin, Sharon R ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiretroviral therapy; HIV 1 cell entry; HIV 1 entry inhibitor; HIV 1 fusion inhibitor

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ENFUVIRTIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; T 1249;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS RESISTANCE;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; MODELS, BIOLOGICAL; RECEPTORS, HIV;

EID: 0037320947     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00111-7     Document Type: Article

References (47)

1. Allaway G., Davis-Bruno K., Beaudry G., Garcia E., Wong E., Ryder A., et al. Expression and characterisation of CD4-Ig2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses. 11:1995;533-539.
2. Bernstein H., Tucher S., Kar S.R., McPherson S.A., McPherson D.T., Dubay J.W., et al. Oligomerization of the hydrophobic heptad repeat of gp41. J. Virol. 69:1995;2745-2750.
3. Bleul C., Farzan M., Choe H., Paroline C., Clark-Lewis I., Sodroski, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:1996;829-833.
4. Cameron P., Freudenthal P., Barker J., Gezelter S., Inaba K., Steinman R. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 257:1992;383-387.
5. Chan D., Fass D., Berger J., Kim P. HIV entry and its inhibition. Cell. 89:1998;263-273.
6. Cocchi F., De Vico A., Garzino-Demo A., Ayra S., Gallo R., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1996;1244-1247.
7. Datema R., Rabin L., Hincenberghs M., Moreno M.B., Warren S., Linquist V., et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM3100), an inhibitor of infectious cell entry. Antimic. Agents Chemother. 40:1996;750-754.
8. De Clercq E., Yamamoto H., Pauuwels R., Balzarini J., Witvrouw M., De Vreese K., et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimic. Agents Chemother. 38:1994;668-674.
9. Deng H., Liu R.H., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
10. Dragic T., Litwin V., Allaway G., Martin S., Huanh Y., Nagashima K., et al. HIV-1 entry into CD4 cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
11. Eckert D., Kim P. Design of potent inhibitors of HIV-1 entry inhibitors from the gp41 N-peptide region. Proc. National Acad. Sci. 98:2001;11187-11192.
12. Eron J, Merigan T, Kilby M, Yangco B, Gleavy J, Rusnak P, et al., A 14-day assessment of the safety, pharmacokinetics and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. Abstract 14. In Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.
13. Esser M., Mori T., Mondor I., Sattentau Q., Dey B., Berger E., et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73:1999;4360-4371.
14. Esté J., Cabrera C., Blanco J., Gutierrez A., Bridget G., Henson G., et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of the formation of syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73:1999;5577-5585.
15. Feng Y., Broder C., Kennedy P., Berger E. HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
16. Fernandez E., Lolis E. Structural studies of chemokines that inhibit HIV-1 entry. Antivir. Chem. Chemother. 12:2001;43-49.
17. Geijtenbeek T., Kwon D., Torensma R., van Vliet S., van duijnhoven C., Middel J., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 100:2000;587-597.
18. Hendrix C., Flexner C., MacFarland R., Giandomenico C., Fuchs E., Redpath E., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:2000;1667-1673.
19. Hu J., Gardner M.F., Miller C. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal innoculation and infects intraepithelial dendritic cells. J. Virol. 74:2000;6087-6095.
20. Jacobson J., Lowy I., Fletcher C., O'Neill T., Tran D., Ketas T., et al. Single dose safety, pharmacological, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:2000;326-329.
21. Kilby J., Hopkins S., Venetta E., DiMassimo B., Cloud G., Lee J., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
22. Lalezari J, Eron J, Carlson M. Sixteen week analysis of heavily pre-treated patients receiving T-20 as a component of multi-drug salvage therapy. Abstract LB-18. In: 39th Interscience Conference on Antimicrobial Agents Chemother, San Diego, CA, September 26-29, 1999.
23. Lalezari J, Drucker J, Demasi R, Hopkins S, Salgo M. A controlled phase II trial assessing three doses of T-20 in combination with abacavir, low dose ritonavir and efavirenz in non-nucleoside naïve protease inhibitor experienced HIV-1-infected adults. Abstract LB5, In Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, Feburary 4-8, 2001.
24. Leonard C., Spellman M., Riddle L., Harris R., Thomas J., Gregory T. Assignment of intrachain disulfide bonds and characterisation of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:1990;10373-10382.
25. Lu M., Blacklow S., Kim P. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1995;1075-1082.
26. Mosier D., Picchio G., Gulizia R., Sabbe R., Poibnard P., Picard L., et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using isolates. J. Virol. 73:1999;3544-3550.
27. Nagashima K., Thompson D., Rosenfield S., Maddon P., Dragic T., Olson W. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:2001;1121-1125.
28. O'Brien W. HIV entry: from molecular insights to specific inhibitors. Medscape http://www.medscape.com July 31, 2001.
29. Olson W., Rabut G., Nagashima K., Tran D., Anselma D., Monard S., et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:1999;4145-4155.
30. Reyes, G. Development of CCR5 antagonists as a new class of HIV-1 therapeutic. Abstract L11. In Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.
31. Rimsky L., Shugars D., Matthews T. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:1998;986-993.
32. Root M., Kay M.A., Kim P. Protein design of an HIV-1 entry inhibitor. Science. 291:2001;884-888.
33. Samson M., Libert F., Doranz B., Rucker J., Liesnard C., Farber C., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725.
34. Sattentau Q. HIV gp120: double lock strategy foils host defences. Structure. 6:1998;945-949.
35. Schupbach J., Gallo R.C. Human retroviruses. Specter S., Hodinka R., Young S. Clinical virology manual. 2001;513-560 ASM Press, Washington, DC.
36. Spira A.I., Marx P.A., et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:1996;215-225.
37. Strizki J.M., Xu S., Wagner N., Wojcik L., Liu J., Hou Y., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Nat. Acad. Sci. 98:2001;12718-12723.
38. Tremblay C., Kollmann C., Tremblay C.L., Kollmann C., Giguel F., Chou T.C., et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immun. Defic. Syndr. 25:2000;99-102.
39. Trkola A., Gordon C., Matthews J., Maxwell E., Ketas T., Czaplewski L., et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J. Virol. 73:1999;6370-6379.
40. Trkola A., Ketas T., Nagashima K., Zhao L., Cilliers T., Morris L., et al. Potent, broad spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:2001;579-588.
41. Turville S., Arthos J., Mac donald K., Lynch G., Naif H., Clark G., et al. HIV gp120 receptors on human dendritic cells. Blood. 98:2001;2482-2488.
42. Weissenhorn W., Wharton S.A., Calder L.J., Earl P.L., Moss B., Aliprandis E., et al. The ectodomain of HIV-1 env subunit gp41forms a soluble alpha-helical, rod-like oligmer in the absence of gp120 and the N-terminal fusion peptide. EMBO. 15:1996;1507-1514.
43. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
44. Wild C., Oas T., McDanal C., Bolognesi D., Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication. Proc. Nat. Acad. Sci. 89:1992;10537-10541.
45. Wu L., Gerard N., Wyatt R., Choe H., Parolin C., Ruffing N., et al. CD-4 induced interacton of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5. Nature. 384:1996;179-183.
46. Wyatt R., Kwong P., Desjardins E., Sweet R., Robinson W., Hendrickson W., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998a;705-711.
47. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1998b;1884-1888.